Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials

被引：98

作者：

McShane, H ^{[1
]}

Pathan, AA ^{[1
]}

Sander, CR ^{[1
]}

Goonetilleke, NP ^{[1
]}

Fletcher, HA ^{[1
]}

Hill, AVS ^{[1
]}

机构：

[1] Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford OX3 7LJ, England

来源：

TUBERCULOSIS | 2005年 / 85卷 / 1-2期

基金：

英国惠康基金;

关键词：

MVA85A; prime-boost; clinical trials;

D O I：

10.1016/j.tube.2004.09.015

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

There is an urgent need for an improved vaccine against tuberculosis. Heterologous prime-boost immunization regimes induce higher levels of cellular immunity than homologous boosting with the same vaccine. Using BCG as the priming immunization in such a regime allows for the retention of the beneficial protective effects of BCG against disseminated disease in childhood. Recombinant poxviruses are powerful boosting agents, for both CD4+ and CD8+ T cells. Here we review the preclinical data from a BCG prime-recombinant modified vaccinia virus Ankara expressing antigen 85A (MVA85A) boost strategy. MVA85A is now in clinical trials in the UK and Africa and the design of these trials, including the ethical and regulatory issues are discussed. (C) 2004 Elsevier Ltd. All rights reserved.

引用

收藏

页码：47 / 52

页数：6

相关论文

共 31 条

[1] Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis [J].

Belisle, JT ;

Vissa, VD ;

Sievert, T ;

Takayama, K ;

Brennan, PJ ;

Besra, GS .

SCIENCE, 1997, 276 (5317) :1420-1422

[2] BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies [J].

Black, GF ;

Weir, RE ;

Floyd, S ;

Bliss, L ;

Warndorff, DK ;

Crampin, AC ;

Ngwira, B ;

Sichali, L ;

Nazareth, B ;

Blackwell, JM ;

Branson, K ;

Chaguluka, SD ;

Donovan, L ;

Jarman, E ;

King, E ;

Fine, PEM ;

Dockrell, HM .

LANCET, 2002, 359 (9315) :1393-1401

[3] Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins:: implications for use as a human vaccine [J].

Blanchard, TJ ;

Alcamí, A ;

Andrea, P ;

Smith, GL .

JOURNAL OF GENERAL VIROLOGY, 1998, 79 :1159-1167

[4] CD8+ T cell-mediated suppression of intracellular Mycobacterium tuberculosis growth in activated human macrophages [J].

Brookes, RH ;

Pathan, AA ;

McShane, H ;

Hensmann, M ;

Price, DA ;

Hill, AVS .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (12) :3293-3302

[5]

Caruso AM, 1999, J IMMUNOL, V162, P5407

[6] EFFICACY OF BCG VACCINE IN THE PREVENTION OF TUBERCULOSIS - METAANALYSIS OF THE PUBLISHED LITERATURE [J].

COLDITZ, GA ;

BREWER, TF ;

BERKEY, CS ;

WILSON, ME ;

BURDICK, E ;

FINEBERG, HV ;

MOSTELLER, F .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (09) :698-702

[7] DISSEMINATED TUBERCULOSIS IN INTERFERON-GAMMA GENE-DISRUPTED MICE [J].

COOPER, AM ;

DALTON, DK ;

STEWART, TA ;

GRIFFIN, JP ;

RUSSELL, DG ;

ORME, IM .

JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (06) :2243-2247

[8] Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals [J].

Cosma, A ;

Nagaraj, R ;

Bühler, S ;

Hinkula, J ;

Busch, DH ;

Sutter, G ;

Goebel, FD ;

Erfle, V .

VACCINE, 2003, 22 (01) :21-29

[9] VARIATION IN PROTECTION BY BCG - IMPLICATIONS OF AND FOR HETEROLOGOUS IMMUNITY [J].

FINE, PEM .

LANCET, 1995, 346 (8986) :1339-1345

[10] AN ESSENTIAL ROLE FOR INTERFERON-GAMMA IN RESISTANCE TO MYCOBACTERIUM-TUBERCULOSIS INFECTION [J].

FLYNN, JL ;

CHAN, J ;

TRIEBOLD, KJ ;

DALTON, DK ;

STEWART, TA ;

BLOOM, BR .

JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (06) :2249-2254

← 1 2 3 4 →